CDH1 and prostate neoplasm: For instance, the recent report of EGFR kinase inhibitors limiting prostate tumour dissemination in experimental models (Angelucci et al, 2006) is likely due to inhibiting pathways and cell behaviors before the proposed upregulation of E-cadherin at the metastatic site, though re-expression of E-cadherin at the primary tumour site would also limit spread by preventing initial detachment (Jawhari et al, 1999; Lowy et al, 2002; Wong and Gumbiner, 2003).